Evidence map›Paper›PMID 42201810›Full record

ArticleCell reports2026

A human corticospinal organoid-slice connectoid model informs enhancer strategies for post-injury axon regrowth.

George M Gibbons, Tanja Fuchsberger, Mai Abdelgawad, Stefano L Giandomenico, Kornélia Szebényi, Veselina Petrova, Lea M D Wenger, Daniel N Olschewski, Jeremi Chabros, Leila Muresan and 7 more

Abstract read
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

George M GibbonsJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Tanja FuchsbergerDepartment of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
Mai AbdelgawadJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Stefano L GiandomenicoMRC Laboratory of Molecular Biology, Cambridge, UK.
Kornélia SzebényiJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Veselina PetrovaJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Lea M D WengerJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Daniel N OlschewskiJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Jeremi ChabrosDepartment of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
Leila MuresanDepartment of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
Rachael C FeordDepartment of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
Muhammad AsifJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
James W FawcettJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Susanna B MierauDepartment of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK; Division of Cognitive and Behavioral Neurology, Brigham & Women's Hospital, Boston, MA, USA.
Ole PaulsenDepartment of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
Madeline A LancasterMRC Laboratory of Molecular Biology, Cambridge, UK.
András LakatosJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK; MRC-WT Cambridge Stem Cell Institute, Cambridge Biomedical Campus, Cambridge, UK. Electronic address: al291@cam.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Axon elongation in the mammalian central nervous system (CNS) declines during development, limiting regenerative capacity after birth. Intrinsic regulators of this process are promising repair targets, as immature axons can regrow in tissues otherwise not conducive to regeneration. Yet the precise timing and mechanisms underlying the cessation of axon growth in the human CNS remain unresolved. Here, we developed a three-dimensional human corticospinal motor organoid-slice connectoid platform mimicking the developmental axon elongation program and its subsequent restriction through maturation. Cortical and spinal slices establish functional connections while remaining spatially segregated, enabling cortical cell-type-specific observations without direct confounding effects by spinal cells. Using single-cell transcriptomics, computational analyses, axon regrowth assays, and live imaging, we identified transcriptional alterations contributing to decreased axon growth in maturing human cortical projection neurons. We further demonstrate that this decline can be reversed using compounds and repurposable drugs targeting a maturation-associated transcriptional shift, promoting post-injury axon repair.

Indexed as

AxonsNerve RegenerationOrganoidsPyramidal TractsHumansamyotrophic lateral sclerosisbrain and spinal cord organoidconnectoidcorticospinal injuryCP: neuroscienceCP: stem cell researchdevelopmental axon growthdrug screeninghuman axon repair failureregenerationsingle-cell genomicsspinal cord injury

Identifiers

PMID42201810
PMCPMC7619264

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.